Cogent Biosciences announces positive initial clinical data from the ongoing Phase 2 APEX study evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM).

Cogent Biosciences, Inc. All patients treated with bezuclastinib achieved ≥50% reduction in serum tryptase, with a median reduction of 89% regardless of prior treatment with the KIT-D816V inhibitor All patients who underwent bone marrow biopsy scored ≥50% reduction in bone marrow mast cells and reduction in allelic fraction of variant KIT D816V in blood (VAF) … Read more